Bristol-Myers Squibb and Gilead Sciences have entered a licensing agreement for the development and commercialisation of a new fixed-dose combination pill for HIV-infected patients.
The combination pill includes Bristol-Myers’ protease inhibitor Reyataz (atazanavir sulfate) and Gilead’s cobicistat, a pharmacoenhancing agent that increases blood levels of certain HIV medicines to enable a dosing of one pill per day.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Reyataz is a prescription drug used in combination with other medicines to treat HIV infected patients aged six or older, and cobicistat is a mechanism-based inhibitor of cytochrome P450 3A, an enzyme that metabolises drugs in the body.
Under the deal, Bristol-Myers will pay Gilead an undisclosed royalty based on annual net sales of the product.
Under the agreement, Bristol-Myers will be responsible for the commercialisation, development, distribution, formulation, manufacturing and registration of Reyataz and cobicistat as a fixed-dose combination.
Gilead will retain exclusive rights to manufacture, develop and market cobicistat as a stand-alone drug and for use in combination with other agents.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData
